Everest Medicines Expands Senior Leadership Team

Sep  2019

Dr. Jason Brown becomes Chief Business Ocer. Dr. Frank Grams as Senior Vice President of Alliance Management and Head of Business Development in Europe

SHANGHAI and NEW YORK, Sept.  16, 2019  (GLOBE NEWSWIRE)  -- Everest  Medicines, a biopharmaceutical  company  focused  on   developing  and   commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and  other  parts of Asia, today  announced Everest  Medicine’s founding member, Dr. Jason Brown, who served as Senior  Vice President of Business Development has  been  named the  company’s Chief Business Ocer.  Additionally, the company announced four senior  leadership appointments, naming  Dr. Frank Grams  as Senior Vice President of Alliance Management, Sophia  Zhu as Senior Vice President of Portfolio   Development and  Strategic Planning,   Alex Wang  as Head  of  International Business and Daniel Weng as Vice President of Finance.


“Jason is a proven senior  business leader  who is committed to further  expansion of the company in Greater  China  and  Asia,”  said  Sean  Cao, PhD,  CEO of Everest  Medicines. “Jason’s  combined business and  scientic acumen have  played  a  signicant part  in helping Everest  Medicines build its current portfolio.  We are excited about the expertise and  depth  that  Jason will continue to add  to our senior  leadership team as we expand the company’s pipeline and business goals.”


To further  strengthen the senior  team,  Everest  Medicines appointed Dr. Frank Grams  as Senior  Vice President of Alliance Management and  Head  of Business  Development in Europe.   Dr.  Grams   brings   more   than   20  years   of  international  experience  in  R&D partnering,  alliance   management,  project   management,  operations  and   risk management. He most recently  served as the  Vice President, Global Head  of Alliance Management for  General  Medicines &  Emerging   Markets and  Global  Head  of  R&D Alliance Management at Sano.


Sophia   Zhu  joins  Everest   Medicines’   Shanghai team as  Senior   Vice  President  of Portfolio  Development and  Strategic Planning. Before  joining  Everest  Medicines, Ms. Zhu served as the  Head  of Strategic Portfolio  Development, Specialty  Care  at  Sano China. Before that, she  served as Director of Worldwide Commercialization, Hepatitis C at Bristol-Myers Squibb.


Alex  Wang   also   joins   the   Everest   Medicines’   Singapore team  as  the   Head   of International Business. Mr. Wang  brings  vast  commercial experience across  diverse geographic  locations.  Previously,   he   served as  the   General   Manager  of  Abbott’s Singapore-based Point-of-Care Division in the Asia Pacic.


Everest  Medicines appointed Daniel Weng as Vice President of Finance. Mr. Weng is a seasoned nancial  professional who has  more  than  20 years  of experience in nancial planning   and  analysis, internal  control,  treasury,  tax,  mergers and  acquisitions, and investment. Before joining Everest  Medicines, he served as Head  of Finance for Amgen China, where  he was  responsible for overall nancial  operations related to commercial operation, research & development activities and strategic collaborations.


“We are  excited to  be  joined  by  these accomplished professionals, each of  whom brings  a  wealth  of  knowledge and  experience to  Everest  Medicines,”  said  Ian  Woo, President  and   CFO  of   Everest   Medicines.  “With  their   unique   qualications  and expertise, we  look  forward  to  expanding and  accelerating our  business development efforts with strategic global partners and further  enhancing our operational capabilities in China.”


About Everest Medicines


Everest  is a biopharmaceutical company focused on developing and  commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and  other  Asian  markets. The management team of Everest has  deep  expertise and  an extensive track  record  of high-quality  clinical development, regulatory affairs,  CMC, business development and  operations both  in China and  with leading   global   pharmaceutical  companies.  For  more   information, please  visit  its website at www.everestmedicines.com.


Contacts:


Media in US and Europe: James Heins

Senior Vice President

ICR Healthcare (203) 856-2121 james.heins@icrinc.com

 


Media in China: Edmond  Lococo Senior Vice President ICR Asia

+86 (10) 6583-7510

edmond.lococo@icrinc.com



info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.